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brochures to access a web-based survey (May 5-July 18, 2014) of demographic & 
disease characteristics, respondents’ lifestyle & health ratings, and their percep-
tion of IV infusions before and after initiating therapy. The analysis was exploratory 
and descriptive; data collected was a self-reported ordinal (scale, low-high, 1-10) 
with medians (IQR) reported. A stepwise (backward) multinomial logistic regres-
sion was conducted to determine predictors of a positive perception of IV infu-
sions. RESULTS: There were 1,762 respondents from 10,000 distributed brochures 
(18%). The majority of patients were: bio-naïve, employed, busy/active, and treated 
for inflammatory bowel disease. Median current health rating was high 8(6-9). The 
perception of IV infusions improved from initial treatment; majority of patients 
rated it as 5/10 prior to starting therapy vs. 8/10 after multiple infusions (p< 0.0001). 
Predictors of a positive IV experience were ‘satisfaction with the PSP coordina-
tor’ (OR= 3.0, 95% CI= 1.5-5.7) and ‘receiving an accurate description of treatment 
through the PSP from a physician’ (OR= 3.6, 95%CI= 2.2-5.9). CONCLUSIONS: 
Although there is selection bias, we found that patients have a positive experience 
with the PSP and report significant improvements in their perception of IV infusion. 
Regression analysis suggests that providing patients with an accurate description of 
the treatment at the PSP can improve the perception of the IV experience.
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OBJECTIVES: Intravenous infusions (IV) vs. subcutaneous injection (SQ) biologic 
products offer advantages and disadvantages to patients with inflammatory bowel 
disease (IBD). This study examines potential predictors of IV vs. SQ openness/pref-
erence among patients with IBD. METHODS: Patients (n= 263) completed a self-
administered, web-based questionnaire assessing demographics, health, disease, 
treatment characteristics, behaviors, and attitudes. Patients included: U.S. adults 
(aged ≥ 18) diagnosed with ulcerative colitis (UC; n= 140), Crohn’s disease (CD; n= 123), 
receiving immunomodulator treatment, but biologics-naïve. Chi square and t tests 
compared patients open vs. not open or preferring vs. not preferring IV. Logistic 
regression models predicted openness and preference as a function of potential pre-
dictors. RESULTS: Among all patients (mean age= 45.8, 57.1% female, 23.5% minority, 
and mean years since diagnosis= 10.7), 74.2% were open to starting biologics after 
discussion with their physicians, 64.6% (n= 170) were open to IV, and among those, 
34.7% (n= 59) preferred IV vs. SQ. Potential predictors of openness to IV included: 
considering one’s physician’s advice to be very-to-extremely influential for treat-
ment decisions (OR= 4.67; 1.87-11.64), male vs. female (OR= 2.94; 1.41-6.10), number 
of emergency room, hospital, and/or physician visits for UC/CD in the past 6 months 
(OR= 1.24; 1.07-1.43), ever experiencing fever as UC/CD sign/symptom (OR= 2.81; 1.21-
6.52), and awareness of infusion for UC/CD (OR= 2.38; 1.10-5.16); intention to delay 
biologics treatment due to safety perceptions inhibited openness to IV (odds ratio 
[OR]= 0.48; 95% confidence interval [CI]: 0.35-0.66); all p< .03. Potential predictors 
of preference for IV over SQ included: higher relative openness to office/hospital/
medical facility vs. home site of care (OR= 5.72: 3.51-9.31), receiving/ever having 
received infusion (OR= 4.11; 1.31-12.95), and detailed discussion of redness/swelling 
after injection (OR= 4.15; 1.29-13.39), all p< .02. CONCLUSIONS: The current study 
helps inform patient characteristics, attitudes, and disease and treatment history 
indicating interest in IV biologics treatment, which can help enable shared decisions 
to best benefit patients with IBD.
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OBJECTIVES: To investigate the relationship between patient-reported outcomes 
and durability of response using data from a phase 2 study of single-agent ibrutinib 
for patients with previously-treated MCL. METHODS: The phase 2 SPARK study 
evaluated the efficacy and safety of single-agent ibrutinib in patients with MCL who 
had received a rituximab-containing regimen and had progressed after ≥ 2 cycles of 
bortezomib therapy. In this multicenter, single-arm study, patients were enrolled to 
receive 560 mg/day ibrutinib continuously until progressive disease (PD) or unac-
ceptable toxicity. The primary end point was the overall response rate in response-
evaluable patients, as assessed by an Independent Review Committee. Secondary 
end points included patient-reported outcomes (FACT-Lym). RESULTS: Overall, 25 
of 110 evaluable patients (22.7%) were considered to have primary resistant disease 
(PD at first disease evaluation), with 85 of 110 (77.3%) considered as “responders”: 
22 patients (20%) were considered to have moderate response (stable disease [SD] 
or better, but with PD within 12 months; MR group), and 63 patients (57.3%) were 
considered to have durable response (SD or better, maintained for > 12 months; 
DR group). Median progression-free survival for the total evaluable population 
was 10.5 months; 4.1 months for the MR group and 16.8 months for the DR group. 
Additionally, 67 of 109 response-evaluable patients who had PRO results (61.5%) 
achieved a clinically-meaningful improvement in lymphoma symptoms based on 
EORTC QLQ-C30 cancer mapping algorithms ranged from 0.70 to 0.92. Utility values 
derived from the two versions of the MF-8D were also within this range, at 0.79 
(equal weighting) and 0.73 (Rasch weighting). Clinical opinion indicated that the 
MF-8D captures the key symptoms of PV (e.g., pruritus, abdominal pain/discomfort, 
bone pain, night sweats) better than the other cancer algorithms. CONCLUSIONS: 
The MF-8D may be more appropriate than other cancer algorithms for estimating 
utility values for PV patients, as it includes the most important symptoms of PV. 
This measure is expected to better capture treatment-specific differences affect-
ing HRQoL that are important for the economic evaluation of emerging therapies.
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OBJECTIVES: Hereditary haemochromatosis (HH) is a common autosomal reces-
sive disorder amongst persons of European heritage. Elevated hepcidin production 
increases the absorption of dietary iron, which is stored in the parenchymal tissues 
of the heart, liver and pancreas. Treatment consists of regular venepuncture, and if 
implemented early, prevents organ damage. If untreated, iron overload can be a cause 
of morbidity and mortality. To date, a lack of robust health economic evidence has 
been cited as one of the barriers to establishing screening programs for HH. Previous 
analyses have used unvalidated estimates of health state utility values (HSUV). This 
is in part due to no published estimates of HSUV. This study sought to estimate HSUV 
directly from people with different levels of severity of HH of in Australia. METHODS: 
Volunteers with HH were recruited to complete a web-based survey as part of a 
national cost of illness study for HH. HSUV was estimated using the Assessment of 
Quality of Life 4D (AQOL-4D) instrument. Severity of HH was categorised according 
to the method recommended by the European Association of the Study of the Liver. 
Multivariate regression analysis was performed to identify parameters associated 
with HSUV. RESULTS: Between November 2013 and November 2014, 221 people com-
pleted the survey. Increasing severity of HH was negatively associated with HSUV. 
Mean (standard deviation) HSUV were 0.76 (0.21), 0.81 (0.18), 0.60 (0.27), and 0.50 (0.27) 
for grades 1-4 HH respectively. CONCLUSIONS: Increasing severity of HH is associated 
with decreasing HSUV. Previous cost utility analyses have used higher HSUV which 
likely resulted in underestimates of the cost effectiveness of screening programs 
for HH. The HSUV reported in this paper are the most robust available and their use 
would improve the validity of future economic models for HH.
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OBJECTIVES: To assess the health status of haemophilia B patients treated with 
nonacog beta pegol, a novel recombinant Factor IX (FIX) product with prolonged 
half-life and less frequent dosing requirements. METHODS: Severe/moderate hae-
mophilia B (FIX activity level ≤ 2%) is an inherited bleeding disorder characterised 
by recurrent, often spontaneous bleeding episodes, in particular musculoskeletal 
bleeds. Modern management includes self-infusion of FIX 2-3 times/week to prevent 
bleeds (prophylaxis) or on-demand treatment (OnD). Haemophilia B patients aged 
13-70 years were included in a single-blind phase 3 trial evaluating safety and effi-
cacy of nonacog beta pegol. Patients were treated OnD for 28 weeks, or randomised 
to once weekly prophylaxis with 10 or 40 IU/kg for 52 weeks. All patients completed 
the 3 level EuroQol-5 dimensions (EQ-5D-3L) at baseline and end-of-trial. EQ-5D VAS 
ranges from 0-100. Higher score represents better health status. Changes in scores 
were compared to no change using the Wilcoxon signed rank test. RESULTS: 74 
patients were included in the Full Analysis Set (15 OnD; 30 on prophylaxis with 10 
IU/kg dose and 29 on prophylaxis with 40 IU/kg). 56 patients were 18-70 years and 18 
were 13-17 years. A significant improvement in EQ-5D index score was observed in 
the overall set (mean change = 0.04, p= 0.016), but no significant change was observed 
for the different dose groups. In subset analysis of the high dose prophylaxis arm, 
mean EQ-5D VAS was 74.3±18.0 at baseline and 83.9±14.5 at end-of-trial, leading to 
a statistically significant improved mean change in score (p= 0.030). The change was 
non-significant in the OnD and low dose prophylaxis arms. CONCLUSIONS: In a 
phase 3 clinical trial, haemophilia B patients treated with the long-acting FIX nona-
cog beta pegol showed a significant improvement in their health status. Patients 
treated with the prophylaxis dose of 40 IU/kg/weekly demonstrated significant 
improvement in health status according to the EQ-5D VAS.
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OBJECTIVES: Patients with auto-immune diseases who are treated with infliximab 
(IFX) intravenous (IV) infusions are managed through a manufacturer-sponsored 
patient support program (PSP). Previous studies have had conflicting conclusions 
regarding patient preferences of modes of administration of biologics, with impli-
cations of negative perceptions of IV infusions. The aim of this study was to assess 
patients’ experience of IFX IV therapy administered in the PSP and to determine 
predictors of a positive perception of IV infusions. METHODS: In this nationwide, 
cross-sectional survey, patients currently receiving IFX within the PSP were given 
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vs. 62%) and have rheumatoid arthritis (62% vs. 43%), 1 or 2 comorbidities (70% vs. 
42%), poorer health status (mean GSRH score, 46 vs 55), on long-term disability 
(13% vs. 2%), and discussed more biologic treatment options (mean number, 3 vs 
2) than non-SDM respondents. Non-SDM respondents were more likely to have 
psoriasis (25% vs. 8%) and no comorbidities (48% vs. 23%) than SDM respondents 
(p< 0.05 for all comparisons). CONCLUSIONS: The preliminary results suggest that 
patients who participate in SDM for biologic therapy initiation differ clinically and 
demographically in comparison to those who do not, however these findings need 
to be confirmed in the final study data.
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OBJECTIVES: A number of new therapeutics are moving into phase 2 clinical tri-
als for treatment of celiac disease (CD), a condition with no treatment other than 
gluten-free diet. Owing to the nature of CD, these trials will require a meaningful and 
validated patient-reported outcome measure (PROM) to quantify the symptomatic 
improvement of patients. The aim of this systematic review is to evaluate PROs for 
suitability in an FDA approval trial for a CD therapeutic. METHODS: A systematic 
search was performed in 5 online databases (MedLine, EmBase, Web of Science, 
CENTRAL, CINAHL) for studies that enrolled patients with CD and used a PROM 
Instruments included inthis review had to measure some PRO concept, be patient 
administered and based upon a previously validated instrument. RESULTS: Our 
literature search identified 2702 unique records of which 157 ultimately qualified 
for abstraction. The majority of studies identified were performed in adults (77%), 
had a cross-sectional design (69%) and were of moderate size (average n= 402). The 
most commonly used PROMs were the SF36, Gastrointestinal Symptom Rating Scale 
(GSRS) and Psychological General Well-Being Measure (PGWB). Only 11% of studies 
identified had a randomized design. Although PROMs specific to CD were identi-
fied they were used only in 10% of studies. CONCLUSIONS: A large literature exists 
of the measurement of QoL in CD patients but PRO instruments used previously 
have been generic health-related QoL instruments unrelated to the specific set of 
symptoms that characterizes CD. Given the limited number of randomized trials in 
CD it is unclear how any of these instruments will perform in the context of trials 
aiming at FDA approval. Better identification of CD-specific concepts and evidence 
of good instrument performance are necessary before a PRO can be relied upon as 
an efficacy measure in CD.
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OBJECTIVES: To identify patient-reported outcome (PRO) measures which were 
used in patients with type 1 myotonic dystrophy (DM1) and to examine the dis-
ease burden on function and health-related quality of life (HRQoL). METHODS: A 
systematic literature review was conducted through PubMed and MEDLINE for PRO 
measures in DM1 as of July 19, 2014. Search keywords were: myotonic dystrophy, 
patient-reported outcome, patient satisfaction, patient preference, patient rating, 
quality of life, and HRQoL. English language articles published between 2000 and 
July 2014 were reviewed. We examined the PRO burden in DM1 patients, with a 
focus on longitudinal studies. In addition, we searched for additional PRO measures 
through clinical trial databases including clinicaltrials.gov and clinicaltrialsregister.
eu. RESULTS: A total of 118 studies were identified in the initial literature search. 
After further review, we found 20 PRO measures in 21 prior studies. In addition, 
we identified two other PRO measures through clinical trial databases. Most of 
the 22 PRO measures identified were generic and covered one or two functional 
or HRQoL domains. The Myotonic Dystrophy Health Index (MDHI) is the only PRO 
measure that was specifically developed for DM1. Based on the literature, DM1 
patients experienced impairment in several domains, including pain, fatigue, and 
sleep disturbances. Only three longitudinal studies were identified and they all indi-
cated significant deterioration in the HRQoL in DM1 patients over time; marked with 
decreased ambulation and increased dependence on others. CONCLUSIONS: There 
are a limited number of studies examining PROs in patients with DM1, which repre-
sents a missed opportunity to understand this complex disease from the patients’ 
perspective. More validation work is needed for existing PRO measures in the DM1 
population to allow use in future drug development. In addition, our study high-
lights the high unmet need for an effective treatment, as prior studies consistently 
reported a substantial PRO burden for DM1.
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OBJECTIVES: Hemophilia A and B are marked by frequent joint bleeding, result-
ing in pain and functional impairment. This study aimed to assess the reliability 
of five PRO instruments in PWH in a non-bleeding state. METHODS: Sequential 
adult male PWH of any severity (with or without inhibitors) with a history of joint 
a change of ≥ 5 points on the FACT-Lym, with 57 of the 80 “responders” who had a 
post-baseline FACT-Lym evaluation (71.3%) achieving this clinically-meaningful level 
of improved quality of life. CONCLUSIONS: Single-agent ibrutinib was highly effica-
cious in this study with a majority of patients responding to therapy and achieving 
long, durable remissions. Moreover, patients with clinical responses to ibrutinib also 
tended to show clinically-meaningful improvements in patient-reported outcomes.
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OBJECTIVES: Psychosocial and environmental factors might have a potential causal 
relationship with chronic pain and the related disability. Psychosocial and environ-
mental factors, socioeconomic status (SES) mediate the relationship among pain, 
disability, and can cause the morbidity and mortality among various conditions. 
Factor analyses of the Pain catastrophizing Scale (PCS) have shown that catastro-
phizing can be viewed as a multidimensional construct comprising elements of 
rumination, magnification and helplessness. The purpose of this study was to 
investigate the correlation between catastrophizing and the level of pain intensity, 
disability, in patients with chronic low back pain (CLBP). METHODS: An observa-
tional study was conducted. Participants were recruited from pain clinic of a public 
tertiary care hospital. Patients of either gender, aged 18–75 years with CLBP for ≥ 
3 months, were eligible for study. Data regarding pain intensity, disability using 
MODQ (Modified Oswestry Disability Questionnaire), coping behaviour using PCS, 
socioeconomic status using Kuppuswamy scale, demographic and disease details 
were collected. Multiple correlation analysis was performed among the clinical 
variables with level of significance of 0.05. RESULTS: A total of 74 patients were 
included in the study. Mean age and duration of low back pain was 46±14 yrs and 
36±32 months respectively. The mean helplessness, magnification and rumination 
were found 11.7±3, 5.5±2 and 7.3±2 respectively. We found a signification positive 
correlation between total PCS and pain intensity (r = 0.66, P = 0.001), disability (r = 
0.67, P = 0.001). Socioeconomic status (r = 0.15, P = 0.09) and duration of low back 
pain (r = 0.06, P = 0.3) was not significantly correlated with total PCS score. A similar 
trend was seen among the subscales of PCS. CONCLUSIONS: Coping behaviours in 
patients was significantly negatively associated with pain intensity and disability. 
Treatment aimed at reducing pain intensity and disability can improve patients 
coping behaviour.
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OBJECTIVES: To identify patient-reported outcome (PRO) instruments used in 
patients with cutaneous lupus erythematosus (CLE). METHODS: A literature search 
was conducted to identify PROs used in CLE patients. We searched PubMed, and 
Web of Science/MEDLINE databases to identify studies using “CLE/cutaneous lupus 
erythematosus,” in combination with PRO-related keywords such as “quality of 
life,” “self-report,” and “instrument.” English language articles published between 
2003 and 2014 were identified. RESULTS: A total of 482 citations were identified in 
the initial search of the journal databases. A total of 305 abstracts were excluded 
as the studies were not conducted in CLE patients, or did not use PRO instruments. 
After reviewing the remaining 177 abstracts in detail, 12 studies were included 
in the final summary review. Aside from generic instruments, potential disease 
related instruments that have been used in CLE patients include Skindex (16 and 29 
items), Dermatology Life Quality Index (DLQI), Body Image Quality of Life Inventory 
(BIQLI), and global assessments of pain and pruritus using Visual Analog Scales 
(VAS). CONCLUSIONS: There is a limited number of studies examining PRO in 
patients with CLE. We identified several dermatology quality of life instruments 
commonly used in CLE patients, but their validity and psychometric properties 
need to be further evaluated to determine whether they are appropriate to use in 
this population. Further studies are needed to better understand the impact of CLE 
from the patient’s perspective.
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OBJECTIVES: To assess the impact of shared decision making (SDM) for initiation 
of biologic therapy on future outcomes and healthcare utilization among patients 
with autoimmune conditions (rheumatoid and psoriatic arthritis, psoriasis, Crohn’s 
disease, ulcerative colitis, and anklyosing spondylitis). Patient characteristics were 
examined among an initial sample of 153 survey respondents. METHODS: Adult 
US health plan commercial enrollees with evidence of an autoimmune condition 
within the prior 6 months and an initial prescription for biologic treatment within 
the prior 2 months were identified in the Optum Research Database and mailed 
a survey in January 2014 (n= 265) and February 2014 (n= 147). Survey measures 
included the SDM Questionnaire (SDM-Q-9), general health status (GSRH), biologic 
treatment options discussed, as well as demographic and clinical characteristics. 
Quan-Charlson comorbidity scores were calculated using administrative claims 
data for the 6 months prior to biologic therapy initiation. Data were compared 
between respondents who participated in SDM and those who did not (non-SDM) 
based on SDM-Q-9 scores. RESULTS: A total of 145 surveys were analyzed (SDM: 
n= 53, non-SDM: n= 92). Respondents were primarily female (68%), Caucasian (91%), 
and 50 years old, on average. SDM respondents were more likely to be female (79% 
